Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Icosavax, Inc. (ICVX)
since 2021 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Icosavax, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1786255.
Total stock buying since 2021: $51,556,893.
Total stock sales since 2021: $6,775,546.
Total stock option exercises since 2021: $1,312,816.
Table 3. Detailed insider trading at Icosavax, Inc. (ICVX)
Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
2024-02-01 | Simpson Adam K. (Chief Executive Officer) | Sale | 15,000 | 15.29 | 229,380 |
2024-02-01 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 15,000 | 1.04 | 15,600 |
2024-01-22 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 98,016 | .94 | 92,135 |
2023-12-21 | Simpson Adam K. (Chief Executive Officer) | Sale | 90,000 | 15.44 | 1,389,150 |
2023-12-21 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 165,917 | 1.45 | 240,579 |
2023-12-20 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 11,884 | 15.46 | 183,690 |
2023-12-20 | Cearley Cassia (Chief Business Officer) | Sale | 7,934 | 15.46 | 122,635 |
2023-12-20 | Simpson Adam K. (Chief Executive Officer) | Sale | 62,205 | 15.46 | 961,502 |
2023-12-20 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 15,183 | 15.46 | 234,744 |
2023-12-13 | Cearley Cassia (Chief Business Officer) | Sale | 8,759 | 16.00 | 140,187 |
2023-08-01 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 3,000 | .84 | 2,520 |
2023-07-31 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 3,323 | 8.86 | 29,448 |
2023-07-31 | Cearley Cassia (Chief Business Officer) | Sale | 1,888 | 8.86 | 16,731 |
2023-07-31 | Simpson Adam K. (Chief Executive Officer) | Sale | 11,788 | 8.86 | 104,465 |
2023-07-31 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 3,066 | 8.86 | 27,170 |
2023-07-03 | Holtzman Douglas (Chief Scientific Officer) | Sale | 16,356 | 9.16 | 149,886 |
2023-07-03 | Holtzman Douglas (Chief Scientific Officer) | Option Ex | 16,356 | 1.04 | 17,010 |
2023-05-23 | Cearley Cassia (Chief Business Officer) | Sale | 10,000 | 10.00 | 100,000 |
2023-04-03 | Holtzman Douglas (Chief Scientific Officer) | Sale | 20,443 | 6.32 | 129,179 |
2023-04-03 | Holtzman Douglas (Chief Scientific Officer) | Option Ex | 20,443 | 1.04 | 21,260 |
2023-03-06 | Cearley Cassia (Chief Business Officer) | Sale | 5,000 | 7.75 | 38,735 |
2023-02-15 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 10,677 | 1.04 | 11,104 |
2023-02-14 | Holtzman Douglas (Chief Scientific Officer) | Sale | 3,349 | 10.17 | 34,066 |
2023-02-13 | Bekiroglu Elizabeth (General Counsel & Corp. Sec.) | Sale | 5,922 | 10.69 | 63,323 |
2023-02-13 | Holtzman Douglas (Chief Scientific Officer) | Sale | 1,522 | 10.69 | 16,274 |
2023-02-13 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 1,794 | 10.69 | 19,183 |
2023-02-13 | Cearley Cassia (Chief Business Officer) | Sale | 1,660 | 10.69 | 17,750 |
2023-02-13 | Simpson Adam K. (Chief Executive Officer) | Sale | 7,506 | 10.69 | 80,261 |
2023-02-13 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 1,902 | 10.69 | 20,338 |
2023-01-30 | Cearley Cassia (Chief Business Officer) | Option Ex | 25,102 | .84 | 21,085 |
2023-01-25 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 13,073 | .94 | 12,288 |
2023-01-04 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 106,373 | 15.70 | 1,670,481 |
2023-01-04 | Kanesa-thasan Niranjan (Chief Medical Officer) | Option Ex | 106,373 | 5.70 | 605,794 |
2022-12-23 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 14,369 | .84 | 12,069 |
2022-12-21 | Simpson Adam K. (Chief Executive Officer) | Sale | 66,764 | 8.96 | 598,405 |
2022-09-08 | Bekiroglu Elizabeth (General Counsel & Corp. Sec.) | Sale | 1,813 | 4.87 | 8,834 |
2022-08-02 | Richardson Charles E (SVP, Technical Operations) | Sale | 371 | 6.70 | 2,487 |
2022-08-02 | Holtzman Douglas (Chief Scientific Officer) | Sale | 453 | 6.70 | 3,036 |
2022-08-02 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 543 | 6.70 | 3,640 |
2022-08-02 | Cearley Cassia (Chief Business Officer) | Sale | 303 | 6.70 | 2,031 |
2022-08-02 | Simpson Adam K. (Chief Executive Officer) | Sale | 1,904 | 6.70 | 12,764 |
2022-08-02 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 495 | 6.70 | 3,318 |
2022-08-01 | Richardson Charles E (SVP, Technical Operations) | Sale | 1,368 | 6.64 | 9,079 |
2022-08-01 | Holtzman Douglas (Chief Scientific Officer) | Sale | 9,337 | 6.64 | 61,969 |
2022-08-01 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 2,001 | 6.64 | 13,280 |
2022-08-01 | Cearley Cassia (Chief Business Officer) | Sale | 1,118 | 6.64 | 7,420 |
2022-08-01 | Simpson Adam K. (Chief Executive Officer) | Sale | 7,017 | 6.64 | 46,571 |
2022-08-01 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 1,825 | 6.64 | 12,112 |
2022-07-29 | Richardson Charles E (SVP, Technical Operations) | Sale | 479 | 7.11 | 3,404 |
2022-07-29 | Holtzman Douglas (Chief Scientific Officer) | Sale | 585 | 7.11 | 4,158 |
2022-07-29 | Kanesa-thasan Niranjan (Chief Medical Officer) | Sale | 701 | 7.11 | 4,982 |
2022-07-29 | Cearley Cassia (Chief Business Officer) | Sale | 391 | 7.11 | 2,779 |
2022-07-29 | Simpson Adam K. (Chief Executive Officer) | Sale | 2,456 | 7.11 | 17,457 |
2022-07-29 | Russo Thomas Joseph (Chief Financial Officer) | Sale | 639 | 7.11 | 4,542 |
2022-07-01 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 7,185 | .84 | 6,035 |
2022-04-01 | Mcdade Mark (Director) | Buy | 42,225 | 7.10 | 299,797 |
2022-03-29 | Shah Rajeev M. | Buy | 8,900 | 4.75 | 42,275 |
2022-03-28 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 4,789 | .84 | 4,022 |
2022-03-28 | Shah Rajeev M. | Buy | 175,318 | 4.53 | 794,541 |
2022-03-18 | Cearley Cassia (Chief Business Officer) | Option Ex | 35,137 | .84 | 29,515 |
2022-03-07 | Cearley Cassia (Chief Business Officer) | Sale | 10,000 | 17.47 | 174,700 |
2022-02-14 | Richardson Charles E (SVP, Technical Operations) | Option Ex | 72,561 | .94 | 68,207 |
2022-02-02 | Kanesa-thasan Niranjan (Chief Medical Officer) | Option Ex | 52,752 | .94 | 49,586 |
2022-01-26 | Simpson Adam K. (Chief Executive Officer) | Option Ex | 90,693 | .94 | 85,251 |
2021-11-15 | Cearley Cassia (Chief Business Officer) | Option Ex | 22,598 | .83 | 18,756 |
2021-08-02 | Kanesa-thasan Niranjan (Chief Medical Officer) | Buy | 6,666 | 15.00 | 99,990 |
2021-08-02 | Nicholson Jonathan (Other) | Buy | 133,334 | 15.00 | 2,000,010 |
2021-08-02 | Shah Rajeev M. | Buy | 2,666,666 | 15.00 | 39,999,990 |
2021-08-02 | Gould Terry P (Director) | Buy | 133,334 | 15.00 | 2,000,010 |
2021-08-02 | Mcdade Mark (Other) | Buy | 221,351 | 15.00 | 3,320,265 |
2021-08-02 | Adams Street Partners Llc | Buy | 133,334 | 15.00 | 2,000,010 |
2021-08-02 | Sanofi (10% Owner) | Buy | 66,667 | 15.00 | 1,000,005 |
Insider trading activities including stock purchases, stock sales, and option exercises
of ICVX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Icosavax, Inc. (symbol ICVX,
CIK number 1786255) see
the Securities and Exchange Commission (SEC) website.